Drug delivery systems and methods for treatment of an eye

• US 20050244465A1
• Filed: 04/30/2004
• Published: 11/03/2005
• Est. Priority Date: 04/30/2004
• Status: Abandoned Application

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Rogers, Victoria, Nivaggioli, Thierry
• Application Number:
  US10/837,291
• Publication Number:
  US 20050244465A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/00 Drugs for disorders of the senses
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

Systems and methods are provided for treatment of an eye. The systems generally include controlled, delayed and or sustained release bioerodible implantable elements having multiple layers of different materials and/or different concentrations of materials. The elements generally include an inner layer, or core, including a therapeutic agent, and one or more outer layers made of polymeric materials, for example substantially pure polymeric materials. The core may include a polymeric material combined with an active agent beneficial in treating a condition of an eye. The elements may be structured such that surfaces of the core are exposed to the physiological environment of the eye when initially implanted within the eye, or may be structured such that the core is entirely enclosed within the outer layers when initially implanted within the eye.

Claims

1. A drug delivery system for modified drug release into an eye comprising:

an element sized and adapted for placement into an eye, said element including a core containing a therapeutic component, a first layer component located on a first side of the core, and a second layer component located on a substantially opposing second side of the core, wherein release of the therapeutic component from the core into the eye is reduced relative to a substantially identical element without the first and second layer components.

2. The system of claim 1 wherein the element has an outer peripheral surface at least a portion of which is free of the first layer component and the second layer component.

3. The system of claim 2 wherein the core has an outer peripheral surface at least a portion of which is free of the first layer component and the second layer component.

4. The system of claim 1 wherein the first layer component includes a first polymeric material and the second layer component includes a second polymeric material.

5. The system of claim 4 wherein the first polymeric material and the second polymeric material are the same material or are different materials.

6. The system of claim 1 wherein the core includes a core polymeric material.

7. The system of claim 1 wherein at least a portion of the element is biodegradable or bioerodible.

8. The system of claim 1 wherein at least one of the first layer component and the second layer component has an aperture therethrough.

9. The system of claim 1 wherein at both of the first layer component and the second layer component have apertures.

10. The system of claim 1 wherein the core has an aperture therethrough.

11. The system of claim 9 wherein the core has an aperture therethrough.

12. The system of claim 8 wherein the aperture is generally centrally located.

13. The system of claim 8 wherein the release of the therapeutic component into the eye is more constant over time relative to a substantially identical element without the aperture.

14. The system of claim 1 wherein the first and second layer components substantially surround an outer portion of the core.

15. The system of claim 1 wherein each of the element includes a gradient of concentrations of the therapeutic component that decreases outwardly from a center of the element.

16. The system of claim 1 wherein the therapeutic component comprises a drug that is soluble in the ocular environment.

17. The system of claim 16 wherein the drug comprises at least one of timolol, timolol maleate, derivatives thereof and mixtures thereof.

18. The system of claim 6 wherein the therapeutic component is substantially insoluble in the ocular environment, and the core polymeric material degrades at a faster rate in the ocular environment than the first and second layer components degrade when in the ocular environment.

19. The system of claim 1 wherein at least one of the first layer component and the second layer component contain an excipient component.

20. The system of claim 19 wherein the excipient component comprises mannitol.

21. The system of claim 17 wherein at least one of the first layer component and the second layer component comprises an excipient component.

22. The system of claim 21 wherein the excipient component comprises mannitol.

23. The system of claim 1 wherein at least one of the first layer component and the second layer component contain a therapeutic component in a concentration less than a concentration of the therapeutic component in the core.

24. A method of treating an eye comprising placing the drug delivery system of claim 1 into an eye.

25. A method of treating an eye comprising placing the drug delivery system of claim 21 into an eye.

27. The system of claim 25 wherein the element has an outer peripheral surface at least a portion of which is free of the first layer component and the second layer component.

29. The system of claim 25 wherein the first polymeric material and the second polymeric material are the same material or are different materials.

30. The system of claim 25 wherein the steroid component is dexamethasone and the first and second polymeric materials are selected from the group consisting of lactic acid polymers, glycolic acid polymers, copolymers of lactic acid and glycolic acid, and combinations thereof.

31. The system of claim 1 wherein at least a portion of the element is biodegradable or bioerodible.

32. The system of claim 25 wherein the first and second layer components substantially surround an outer portion of the core.

33. The system of claim 25 wherein at least one of the first layer component and the second layer component contain an excipient component.

34. The system of claim 25 wherein at least one of the first layer component and the second layer component contain a therapeutic component.

35. A method of treating an inflammatory condition of an eye, the method comprising placing the drug delivery system of claim 25 into an eye.

36. A method of treating an inflammatory condition of an eye, the method comprising placing the drug delivery system of claim 29 into an eye.

26. A drug delivery system for modified drug release into an eye comprising. an element sized and adapted for placement into an eye, said element including a core containing a steroid component, a first layer component located on a first side of the core and including a first polymeric material, and a second layer component located on a substantially opposing second side of the core and including a second polymeric material, wherein release of the steroid component from the core into the eye is reduced relative to a substantially identical element without the first and second layer components.

28. The system of claim 26 wherein the core has an outer peripheral surface which is free of the first layer component and the second layer component.